IRIS

IRIS Home | Critical Effect Search Results

Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the RfD, RfC, oral slope factor, or inhalation unit risk. Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see Quick Check: Assessments in Development.

Search Filtered by: Critical Effect = "Hepatic"
Number of records: 130
Chemical Name CASRN Exposure Route Critical Effect RfD/RfC RfD/RfC Value
Acenaphthene 83-32-9 Oral Hepatotoxicity RFD 6 x 10 -2 mg/kg-day
Acetochlor 34256-82-1 Oral Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males RFD 2 x 10 -2 mg/kg-day
Aldrin 309-00-2 Oral Liver toxicity RFD 3 x 10 -5 mg/kg-day
Allyl alcohol 107-18-6 Oral Impaired renal function and increased liver and kidney weights RFD 5 x 10 -3 mg/kg-day
Amdro 67485-29-4 Oral Increased organ weights RFD 3 x 10 -4 mg/kg-day
Ametryn 834-12-8 Oral Liver toxicity RFD 9 x 10 -3 mg/kg-day
Apollo 74115-24-5 Oral Liver effects; organ weight changes RFD 1.3 x 10 -2 mg/kg-day
Assure 76578-14-8 Oral Liver cell enlargement RFD 9 x 10 -3 mg/kg-day
Asulam 3337-71-1 Oral Lower ovarian weight, lower liver/body weight RFD 5 x 10 -2 mg/kg-day
Benzidine 92-87-5 Oral Brain cell vacuolization; liver cell alterations in females RFD 3 x 10 -3 mg/kg-day
Bromobenzene 108-86-1 Inhalation Hepatocellular cytomegaly in female B6C3F1 mice RFC 6 x 10 -2 mg/m3
Bromobenzene 108-86-1 Oral Hepatocellular cytomegaly in male B6C3F1 mice RFD 8 x 10 -3 mg/kg-day
Bromobenzene 108-86-1 Oral Hepatocellular cytomegaly in male B6C3F1 mice RFD 2 x 10 -2 mg/kg-day
Bromobenzene 108-86-1 Inhalation Hepatocellular cytomegaly in female B6C3F1 mice RFC 2 x 10 -1 mg/m3
Bromoform 75-25-2 Oral Hepatic lesions RFD 2 x 10 -2 mg/kg-day
Butyl benzyl phthalate (BBP) 85-68-7 Oral Significantly increased liver-to-body weight and liver-to-brain weight ratios RFD 2 x 10 -1 mg/kg-day
Butylate 2008-41-5 Oral Increased relative liver weight in male dogs RFD 5 x 10 -2 mg/kg-day
Carbaryl 63-25-2 Oral Kidney and liver toxicity RFD 1 x 10 -1 mg/kg-day
Carbon tetrachloride 56-23-5 Inhalation Fatty changes in the liver RFC 1 x 10 -1 mg/m3
Carbon tetrachloride 56-23-5 Oral Elevated serum SDH activity RFD 4 x 10 -3 mg/kg-day
Chloramben 133-90-4 Oral Hepatocyte degeneration RFD 1.5 x 10 -2 mg/kg-day
Chlordane (Technical) 12789-03-6 Oral Hepatic necrosis RFD 5 x 10 -4 mg/kg-day
Chlordane (Technical) 12789-03-6 Inhalation Hepatic effects RFC 7 x 10 -4 mg/m3
Chlorobenzene 108-90-7 Oral Histopathologic changes in liver RFD 2 x 10 -2 mg/kg-day
Chloroform 67-66-3 Oral Moderate/marked fatty cyst formation in the liver and elevated SGPT RFD 1 x 10 -2 mg/kg-day
beta-Chloronaphthalene 91-58-7 Oral Dyspnea, abnormal appearance, liver enlargement RFD 8 x 10 -2 mg/kg-day
Chlorpropham 101-21-3 Oral Kidney, spleen, liver, and bone marrow toxicity RFD 2 x 10 -1 mg/kg-day
Copper cyanide 544-92-3 Oral Decreased body and organ weights, histopathologic alterations in liver and kidney RFD 5 x 10 -3 mg/kg-day
Dacthal 1861-32-1 Oral Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females RFD 1 x 10 -2 mg/kg-day
Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Oral Increased relative liver weight RFD 2 x 10 -2 mg/kg-day
Di(2-ethylhexyl)adipate 103-23-1 Oral Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size RFD 6 x 10 -1 mg/kg-day
1,4-Dibromobenzene 106-37-6 Oral Liver/body weight ratio and hepatic microsomal enzyme induction RFD 1 x 10 -2 mg/kg-day
Dibromochloromethane 124-48-1 Oral Hepatic lesions RFD 2 x 10 -2 mg/kg-day
1,2-Dibromoethane 106-93-4 Oral Testicular atrophy, liver peliosis, and adrenal cortical degeneration RFD 9 x 10 -3 mg/kg-day
Dichloroacetic acid 79-43-6 Oral Lesions observed in the testes, cerebrum, cerebellum, and liver. RFD 4 x 10 -3 mg/kg-day
1,4-Dichlorobenzene 106-46-7 Inhalation Increased liver weights in P1 males RFC 8 x 10 -1 mg/m3
p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Oral Liver lesions RFD 5 x 10 -4 mg/kg-day
1,1-Dichloroethylene (1,1-DCE) 75-35-4 Oral Liver toxicity (fatty change) RFD 5 x 10 -2 mg/kg-day
1,1-Dichloroethylene (1,1-DCE) 75-35-4 Inhalation Liver toxicity (fatty change) RFC 2 x 10 -1 mg/m3
Dichloromethane 75-09-2 Inhalation Hepatic effects (hepatic vacuolation) RFC 6 x 10 -1 mg/m3
Dichloromethane 75-09-2 Oral Hepatic effects (hepatic vacuolation, liver foci) RFD 6 x 10 -3 mg/kg-day
2,4-Dichlorophenoxyacetic acid (2,4-D) 94-75-7 Oral Hematologic, hepatic and renal toxicity RFD 1 x 10 -2 mg/kg-day
2,3-Dichloropropanol 616-23-9 Oral Myocardial degeneration, hepatotoxicity and nephrotoxicity RFD 3 x 10 -3 mg/kg-day
Dieldrin 60-57-1 Oral Liver lesions RFD 5 x 10 -5 mg/kg-day
Dimethipin 55290-64-7 Oral Increased absolute and relative liver weight RFD 2 x 10 -2 mg/kg-day
N,N-Dimethylformamide 68-12-2 Inhalation Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities RFC 3 x 10 -2 mg/m3
3,4-Dimethylphenol 95-65-8 Oral Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen RFD 1 x 10 -3 mg/kg-day
2,6-Dimethylphenol 576-26-1 Oral Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) RFD 6 x 10 -4 mg/kg-day
2,4-Dinitrotoluene 121-14-2 Oral Neurotoxicity, Heinz bodies and biliary tract hyperplasia RFD 2 x 10 -3 mg/kg-day
1,4-Dioxane 123-91-1 Oral Liver and kidney toxicity RFD 3 x 10 -2 mg/kg-day
Diphenamid 957-51-7 Oral Liver toxicity RFD 3 x 10 -2 mg/kg-day
Diphenylamine 122-39-4 Oral Decreased body weight gain, and increased liver and kidney weights RFD 2.5 x 10 -2 mg/kg-day
Endrin 72-20-8 Oral Mild histological lesions in liver, occasional convulsions RFD 3 x 10 -4 mg/kg-day
Ethylbenzene 100-41-4 Oral Liver and kidney toxicity RFD 1 x 10 -1 mg/kg-day
Fluoranthene 206-44-0 Oral Nephropathy, increased liver weights, hematological alterations, and clinical effects RFD 4 x 10 -2 mg/kg-day
Flurprimidol 56425-91-3 Oral Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) RFD 2 x 10 -2 mg/kg-day
Flutolanil 66332-96-5 Oral Decreased body weight and body weight gains in both doses increased liver weights at high dose RFD 6 x 10 -2 mg/kg-day
Folpet 133-07-3 Oral Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) RFD 1 x 10 -1 mg/kg-day
Fonofos 944-22-9 Oral Cholinesterase inhibition, cholinergic symptoms, and increased liver weight RFD 2 x 10 -3 mg/kg-day
Furan 110-00-9 Oral Hepatic lesions RFD 1 x 10 -3 mg/kg-day
Furfural 98-01-1 Oral Mild hepatocellular vacuolization RFD 3 x 10 -3 mg/kg-day
Heptachlor 76-44-8 Oral Liver weight increases in males RFD 5 x 10 -4 mg/kg-day
Heptachlor epoxide 1024-57-3 Oral Increased liver-to-body weight ratio in both males and females RFD 1.3 x 10 -5 mg/kg-day
Hexabromobenzene 87-82-1 Oral Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins RFD 2 x 10 -3 mg/kg-day
Hexachlorobenzene 118-74-1 Oral Liver effects RFD 8 x 10 -4 mg/kg-day
gamma-Hexachlorocyclohexane (gamma-HCH) 58-89-9 Oral Liver and kidney toxicity RFD 3 x 10 -4 mg/kg-day
Imazaquin 81335-37-7 Oral Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK RFD 2.5 x 10 -1 mg/kg-day
Isoxaben 82558-50-7 Oral Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight RFD 5 x 10 -2 mg/kg-day
Lactofen 77501-63-4 Oral Increased absolute and relative liver weight; hepatocytomegaly in males RFD 2 x 10 -3 mg/kg-day
Londax 83055-99-6 Oral Liver effects RFD 2 x 10 -1 mg/kg-day
Metalaxyl 57837-19-1 Oral Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio RFD 6 x 10 -2 mg/kg-day
Methacrylonitrile 126-98-7 Oral Increased SGOT and SGPT levels RFD 1 x 10 -4 mg/kg-day
Methidathion 950-37-8 Oral Liver toxicity RFD 1 x 10 -3 mg/kg-day
Methyl tert-butyl ether (MTBE) 1634-04-4 Inhalation Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) RFC 3 mg/m3
4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 Oral Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights RFD 1 x 10 -2 mg/kg-day
2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 Oral Kidney and liver toxicity RFD 5 x 10 -4 mg/kg-day
Metribuzin 21087-64-9 Oral Liver and kidney effects, decreased body weight, mortality RFD 2.5 x 10 -2 mg/kg-day
Mirex 2385-85-5 Oral Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles RFD 2 x 10 -4 mg/kg-day
2-Nitropropane 79-46-9 Inhalation Liver focal vacuolization and nodules RFC 2 x 10 -2 mg/m3
Norflurazon 27314-13-2 Oral Liver and thyroid effects RFD 4 x 10 -2 mg/kg-day
NuStar 85509-19-9 Oral Liver cell enlargement RFD 7 x 10 -4 mg/kg-day
Octabromodiphenyl ether 32536-52-0 Oral Induction of hepatic enzymes; liver histopathology RFD 3 x 10 -3 mg/kg-day
Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 Oral Hepatic lesions RFD 5 x 10 -2 mg/kg-day
Oryzalin 19044-88-3 Oral Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights RFD 5 x 10 -2 mg/kg-day
Oxadiazon 19666-30-9 Oral Increased levels of serum proteins and increased liver weights RFD 5 x 10 -3 mg/kg-day
Oxyfluorfen 42874-03-3 Oral Increased absolute liver weight and nonneoplastic lesions RFD 3 x 10 -3 mg/kg-day
Paclobutrazol 76738-62-0 Oral Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels RFD 1.3 x 10 -2 mg/kg-day
Pendimethalin 40487-42-1 Oral Increase in serum alkaline phosphatase and liver weight, and hepatic lesions RFD 4 x 10 -2 mg/kg-day
Pentabromodiphenyl ether 32534-81-9 Oral Induction of hepatic enzymes RFD 2 x 10 -3 mg/kg-day
Pentachlorobenzene 608-93-5 Oral Liver and kidney toxicity RFD 8 x 10 -4 mg/kg-day
Pentachloronitrobenzene (PCNB) 82-68-8 Oral Liver toxicity RFD 3 x 10 -3 mg/kg-day
Pentachlorophenol 87-86-5 Oral Hepatotoxicity RFD 5 x 10 -3 mg/kg-day
Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) RFD 1 x 10 -3 mg/kg-day
Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Increased hepatocellular hypertrophy RFD 1 x 10 -2 mg/kg-day
Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Increased hepatocellular hypertrophy RFD 1 x 10 -3 mg/kg-day
Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats RFD 4 x 10 -4 mg/kg-day
Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Increased hepatocellular hypertrophy in adult rats RFD 1 x 10 -3 mg/kg-day
Permethrin 52645-53-1 Oral Increased liver weights RFD 5 x 10 -2 mg/kg-day
m-Phenylenediamine 108-45-2 Oral Increased relative and absolute liver weights and degenerative liver lesions RFD 6 x 10 -3 mg/kg-day
Phosmet 732-11-6 Oral Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition RFD 2 x 10 -2 mg/kg-day
Picloram 1918-02-1 Oral Increased liver weights RFD 7 x 10 -2 mg/kg-day
Prochloraz 67747-09-5 Oral Increase in SAP and liver weights, liver histopathology RFD 9 x 10 -3 mg/kg-day
Prometryn 7287-19-6 Oral Liver and kidney degeneration and bone marrow atrophy RFD 4 x 10 -3 mg/kg-day
Propachlor 1918-16-7 Oral Decreased weight gain, food consumption increased relative liver weights RFD 1.3 x 10 -2 mg/kg-day
Propargyl alcohol 107-19-7 Oral Renal and hepatotoxicity RFD 2 x 10 -3 mg/kg-day
Pyridine 110-86-1 Oral Increased liver weight RFD 1 x 10 -3 mg/kg-day
Styrene 100-42-5 Oral Red blood cell and liver effects RFD 2 x 10 -1 mg/kg-day
Terbacil 5902-51-2 Oral Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase RFD 1.3 x 10 -2 mg/kg-day
1,1,2,2-Tetrachloroethane 79-34-5 Oral Increased relative liver weight in rats RFD 5 x 10 -2 mg/kg-day
1,1,2,2-Tetrachloroethane 79-34-5 Oral Increased relative liver weight in rats RFD 2 x 10 -2 mg/kg-day
1,1,1,2-Tetrachloroethane 630-20-6 Oral Mineralization of the kidneys in males, hepatic clear cell change in females RFD 3 x 10 -2 mg/kg-day
2,3,4,6-Tetrachlorophenol 58-90-2 Oral Increased liver weights and centrilobular hypertrophy RFD 3 x 10 -2 mg/kg-day
Tetrachlorovinphos 961-11-5 Oral Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition RFD 3 x 10 -2 mg/kg-day
Tetraethyl lead 78-00-2 Oral Histopathology of liver and thymus RFD 1 x 10 -7 mg/kg-day
Tetrahydrofuran 109-99-9 Inhalation Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) RFC 2 mg/m3
Triallate 2303-17-5 Oral Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females RFD 1.3 x 10 -2 mg/kg-day
Triasulfuron 82097-50-5 Oral Centrilobular hepatocytomegaly in males RFD 1 x 10 -2 mg/kg-day
1,2,4-Tribromobenzene 615-54-3 Oral Increased liver-to-body weight ratio and hepatic microsomal enzyme induction RFD 5 x 10 -3 mg/kg-day
Trichloroacetic acid 76-03-9 Oral Hepatocellular necrosis RFD 2 x 10 -2 mg/kg-day
1,1,1-Trichloroethane 71-55-6 Inhalation Liver histopathologic changes RFC 5 mg/m3
1,1,1-Trichloroethane 71-55-6 Inhalation Liver histopathologic changes RFC 5 mg/m3
2,4,5-Trichlorophenol 95-95-4 Oral Liver and kidney pathology RFD 1 x 10 -1 mg/kg-day
2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) 93-72-1 Oral Histopathological changes in liver RFD 8 x 10 -3 mg/kg-day
1,2,3-Trichloropropane 96-18-4 Oral Increased absolute liver weight in male rats RFD 4 x 10 -3 mg/kg-day
1,1,2-Trichloropropane 598-77-6 Oral Mild lesions in liver, kidney and thyroid RFD 5 x 10 -3 mg/kg-day
Trifluralin 1582-09-8 Oral Increased liver weights; increase in methemoglobin RFD 7.5 x 10 -3 mg/kg-day
2,4,6-Trinitrotoluene (TNT) 118-96-7 Oral Liver effects RFD 5 x 10 -4 mg/kg-day
Vinyl bromide 593-60-2 Inhalation Hypertrophy, basophilic and eosinophilic foci, in the liver RFC 3 x 10 -3 mg/m3
Vinyl chloride 75-01-4 Oral Liver cell polymorphism RFD 3 x 10 -3 mg/kg-day
Vinyl chloride 75-01-4 Inhalation Liver cell polymorphism RFC 1 x 10 -1 mg/m3